Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
MedBiome General Information
MedBiome has developed the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes. They also reported the effects of berberine (BBR) and 16 structural analogs on seven individual gut microbiomes using their RapidAIM technology
Contact Information
Drug Pipeline
No pipeline data available
Key Partnerships
University of Ottawa
MedBiome Funding
No funding data available
To view MedBiome's complete valuation and funding history, request access »